Early access
Sign in
Taking people in GermanyPhase 1

Studies how one dose of NNC0537-1482 moves through the body in kidney function

Tests how NNC0537-1482 is processed in adults with normal or reduced kidney function.

Key facts

Who runs it
Novo Nordisk A/S
Where
Berlin, GermanySee the site
Registry title
A research study looking into how a single dose of the medicine NNC0537-1482 moves through the body of participants with normal or reduced kidney function
Status
Recruiting
Phase
Phase 1
People taking part
54 people, planned
Started
31 Aug 2026
Expected to end
6 Jul 2027
Type of study
Interventional
Record updated
19 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with normal or reduced kidney function to study how a single dose of NNC0537-1482 moves through the body.

Age
18 years or older
Sex
Women and men can join.

Where in Germany

  • Charite Research Organisation GmbHBerlin, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Studies how one dose of NNC0537-1482 moves through the body in kidney functionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
19 October 2026